Related Experiment Video

Updated: Oct 9, 2025

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing
12:45

Benefits of Cardiac Resynchronization Therapy in an Asynchronous Heart Failure Model Induced by Left Bundle Branch Ablation and Rapid Pacing

Published on: December 11, 2017

10.6K

Monocyte Subsets in Patients with Chronic Heart Failure Treated with Cardiac Resynchronization Therapy

Katarzyna Ptaszyńska-Kopczyńska1, Andrzej Eljaszewicz2, Marta Marcinkiewicz-Siemion1

  • 1Department of Cardiology, Medical University of Białystok, ul. Skłodowskiej-Curie 24A, 15-089 Białystok, Poland.

Cells
|December 24, 2021
PubMed

Insights

Heart failure with reduced ejection fraction (HFrEF) alters monocyte subsets. Cardiac resynchronization therapy (CRT) in HFrEF patients normalizes these monocyte levels, suggesting CRT

Area of Science:

  • Immunology
  • Cardiology
  • Biomedical Science

Background:

  • The precise role of inflammatory factors in heart failure with reduced ejection fraction (HFrEF) requires further elucidation.
  • Monocyte subsets, including classical (CD14++CD16-), intermediate (CD14++CD16+), and non-classical (CD14+CD16++), are implicated in cardiovascular disease.
  • Understanding monocyte compartment dynamics in HFrEF is crucial for developing targeted therapies.

Purpose of the Study:

  • To investigate the frequencies of three distinct monocyte subsets in patients diagnosed with HFrEF.
  • To evaluate the impact of cardiac resynchronization therapy (CRT) on the composition of the monocyte compartment in HFrEF patients.
  • To compare monocyte subset profiles between HFrEF patients and healthy controls.

Main Methods:

  • Inclusion of 85 stable HFrEF patients and 23 healthy volunteers as a control group.
  • Subgroup analysis of 25 HFrEF patients who underwent cardiac resynchronization therapy (CRT) implantation.
  • Flow cytometry analysis to quantify classical, intermediate, and non-classical monocyte subsets at baseline and 6 months post-CRT.

Main Results:

  • HFrEF patients exhibited significantly lower frequencies of non-classical CD14+CD16++ monocytes compared to controls (p=0.021).
  • Following CRT, a significant increase in non-classical CD14+CD16++ (p=0.042) and intermediate CD14++CD16+ (p=0.017) monocytes was observed.
  • Cardiac resynchronization therapy also led to a significant decrease in the frequency of steady-state classical CD14++CD16- monocytes (p=0.003) in HFrEF patients.

Conclusions:

  • Heart failure with reduced ejection fraction is associated with an altered monocyte subset composition.
  • Cardiac resynchronization therapy effectively modulates the monocyte compartment in HFrEF patients.
  • Post-CRT monocyte profiles in HFrEF patients approximate those found in individuals without heart failure.
Abstract

Keywords:
cardiac resynchronization therapychemokinesheart failureiron homeostasismonocytes

More Related Videos

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes08:47

Evaluation of Cardiac Contractility Modulation Therapy in 2D Human Stem Cell-Derived Cardiomyocytes

Published on: December 16, 2022

2.6K
Intramyocardial Cell Delivery: Observations in Murine Hearts08:12

Intramyocardial Cell Delivery: Observations in Murine Hearts

Published on: January 24, 2014

13.7K

Related Concept Videos

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
50
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
60
Heart Failure II: Pathophysiology01:29

Heart Failure II: Pathophysiology

Systolic Heart Failure and Compensatory MechanismsSystolic heart failure (also termed HFrEF, Heart Failure with Reduced Ejection Fraction) is the most prevalent type of heart filure. It results in a decreased volume of blood being pumped from the ventricle. The aortic arch and carotid sinuses have baroreceptors that detect reduced blood pressure, triggering the sympathetic nervous system (SNS) to release epinephrine and norepinephrine. Initially, this response aims to boost heart rate and...
96
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
60
Heart Failure III: Clinical Manifestations01:26

Heart Failure III: Clinical Manifestations

Heart failure (HF) manifests primarily as dyspnea, fatigue, and fluid retention, resulting in peripheral and pulmonary edema. Symptoms may vary depending on which ventricle is more affected, left or right.Left-Sided Heart FailureAlso known as left ventricular failure, this condition results from the left ventricle's inability to fill or eject sufficient blood into the systemic circulation. It leads to pulmonary congestion, which occurs when the left ventricle fails to eject blood effectively...
81
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
43